Factors such as the rising prevalence of infectious diseases and the introduction of newer pathogens, the need for prompt diagnosis, the increasing number of blood transfusions and donations, and the cost-benefits of INAAT are the key factors driving the market growth.
The report "Isothermal Nucleic Acid Amplification Technology/INAAT Market size is expected to grow from USD 1.9 billion in 2019 to USD 3.3 billion by 2024, at a CAGR of 11.0% during the forecast period.
Download PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=839
Based on the product, the INAAT market is segmented into assay, kits, and reagents, and systems. Assay, kits, and reagents segment are expected to account for the largest share of the INAAT industry in 2019, owing to the factors such as the increasing number of infectious disease diagnostic tests carried out; the growing prevalence of infectious diseases.
Based on the type, the global market is divided into TMA, LAMP, SDA, HAD, NASBA, and other technologies. The TMA segment is expected to account for the largest share of the global INAAT industry in 2019. The large share of this segment is attributed to the growing reliance on POC diagnosis in hospitals and blood banks.
Based on application, the INAAT market is segmented into infectious disease diagnosis, blood screening, and other applications such as cancer diagnosis, cancer research, and laboratory research, which encompass cDNA preparation, whole-genome amplification (WGA), single-nucleotide polymorphism (SNP), and mutation analysis.
Based on the end user, the market is divided into hospitals, reference laboratories, academic and research institutes, and other end users.
In 2019, North America is expected to account for the largest share of the global INAAT market, followed by Europe.
The major companies in the global INAAT market include Grifols S.A. (Spain), Hologic, Inc. (US), Abbott Laboratories, Inc. (US), Becton, Dickinson & Company (US), and Meridian Bioscience (US).
No comments:
Post a Comment